Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields

Naoki Aikawa, Junichi Sasaki, Shigetomi Iwai, Masahiko Kunimatsu, Hisashi Furuhata, Tetsuya Watanabe, Hideki Matsuyama, Yuji Sugiyama, Takeaki Shimizu, Nagao Shinagawa, Keiji Mashita, Tadao Manabe, Shu Ishikawa, Akira Mizuno, Akihiko Iwai, Kazuaki Matsumoto, Keiichi Hori, Hiroaki Kinoshita, Shoji Kubo, Hiromu TanakaTakami Ueda, Mikio Fujimoto, Shuichi Nakatani, Ryutaro Iwasa, Osamu Yamazaki, Takashi Yokoyama, Takashi Kodama, Nobukazu Miyoshi, Yasushi Maruyama, Akihiro Kishi, Gen Takesawa, Seiji Matsuda, Hiroji Okada, Yoshinori Nakata, Jiro Okumura, Tadashi Obata, Shigeatsu Endo, Kazuyoshi Saito, Yoshiki Takahashi, Yoshimi Osakabe, Chiiho Fujii, Mitsuhiro Fukuda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A clinical investigation of intravenous ciprofloxacin (CPFX) in the surgical and gynecological fields was conducted in patients with sepsis, peritonitis, biliary tract infections, secondary infections (due to trauma, burns and operative wounds) and gynecological infections, all of which were severe and/or refractory. CPFX was administered intravenously 300 mg twice a day for 3 to 14 days to 87 patients: 4 with sepsis, 22 with peritonitis, 11 with biliary tract infections, 33 with secondary infections, 13 with gynecological infections and 4 with other infections. The clinical efficacy rate was 85.1% (63/74 cases): 100% (2/2 cases) with sepsis, 88.2% (15/17 cases) with peritonitis, 63.6% (7/11 cases) with biliary tract infections, 90.6% (29/32 cases) with secondary infections and 83.3% (10/12 cases) with gynecological infections. The eradication rate of causative organisms was 67.9% (55/81 strains) in terms of bacteriological efficacy. Side effects were noted in 1 case (1.2%) who developed anemia. Abnormal laboratory findings were observed in 18 cases (21.2%) and major findings were increased eosinophil counts and elevated transaminases. The evaluations of overall safety and usefulness were 80.0% (68/85 cases) and 83.8% (62/74 cases), respectively. Therefore, we found that intravenous CPFX is a highly effective drugs for severe and /or refractory surgical infections in the surgical and gynecological fields.

Original languageEnglish
Pages (from-to)948-950
Number of pages3
JournalJapanese Journal of Chemotherapy
Volume45
Issue number11
Publication statusPublished - 1997 Dec 1

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Aikawa, N., Sasaki, J., Iwai, S., Kunimatsu, M., Furuhata, H., Watanabe, T., Matsuyama, H., Sugiyama, Y., Shimizu, T., Shinagawa, N., Mashita, K., Manabe, T., Ishikawa, S., Mizuno, A., Iwai, A., Matsumoto, K., Hori, K., Kinoshita, H., Kubo, S., ... Fukuda, M. (1997). Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields. Japanese Journal of Chemotherapy, 45(11), 948-950.